Recent studies highlight the effectiveness of GLP-1 receptor agonists in treating various obesity-related conditions. Eli Lilly's GLP-1 drug, in particular, has shown promising results in reducing symptoms of sleep apnea in obese or overweight patients, potentially reducing the need for CPAP machines and offering insurance savings. Additionally, semaglutide has demonstrated effectiveness in treating obesity-related heart failure with preserved ejection fraction and type 2 diabetes, showing greater reductions in symptoms and physical limitations compared to placebo in the STEP-HFpEF DM trial. These findings underscore the growing importance of GLP-1 drugs in addressing complex health issues linked to obesity, with a notable 20% weight loss contributing to these outcomes.
I was at first excited to see this free CME offering by @NEJM on Lifestyle Interventions in the Management of Obesity. The sponsorship by pharma makes me wonder how effective the lifestyle recommendations will actually be. What do you think? https://t.co/twlTTdTRlv
(Bloomberg) - A surprising thing is happening to some women on weight-loss drugs who’ve struggled with fertility issues: They’re getting pregnant .. @business @JohnSpall247 $NVO https://t.co/xvWOMViJgQ
$NVO $LLY Ozempic ‘Oops’ Babies Spark Debate About Weight-Loss Shot Use as Fertility Drugs - BBG https://t.co/y9Bu7v1ZzS
Top 6 barriers to #obesity treatment: inadequate finance, lack of obesity training, obesity not recognised as a disease, lack of specialist teams, lack of public awareness & the obesogenic environment. 🚨 #UHC isn’t possible without addressing these! #HealthforAll https://t.co/NO8c6lD3h2
❗️ Weight stigma has been identified as a social determinant of health that is a barrier to health equity. It leads to systemic disadvantages, inequities, numerous adverse health consequences and discrimination – making it a human rights issue. ➡️ https://t.co/JQIS7mBX9F https://t.co/Am4ZFyHXU1
Remarkably good news for people with #obesity and #SleepApnea. Treatment with #tizepatide yields “phenomenal” results. HT: @EliLillyandCo https://t.co/h325E7F2I5
Two New Studies Suggest a Sleep Apnea Benefit for #Tirzepatide - @ConscienHealth https://t.co/qjiBAfCAOW
Why should advanced obesity care go primarily to the few and the wealthy? Great piece from @ConscienHealth https://t.co/HMipF83JYV
Obesity is a growing issue with deep, societal roots that requires decisive action from everyone. ❗ Read our latest global study on its global economic impact and what can be done to help. ➡️ https://t.co/HmJj8ms7k0 https://t.co/P4YT30zb0m
Bold. Proposed resource allocation of GLP+ drugs for #obesity: https://t.co/LiNly4b2EB @nejm While I agree with the underlying intent (ie, how to provide the most benefit with limited resources), some of this echoes uncomfortably of insurance barriers
Top-line results for #SurmountOSA, a Ph3 trial investigating the use of #Tirzepatide for ppl with obesity and OSA https://t.co/BKchCdGiKM
Among patients with obesity-related heart failure with preserved ejection fraction & type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations & body weight than placebo at 1 year. Full STEP-HFpEF DM trial results: https://t.co/TbIZ7t391g #ACC24 https://t.co/hPHPNvlIsz
On the great news re: Lilly's GLP-1 drug & sleep apnea, does this also reduce the patient's need for CPAP machines and save the insurance company $ on equipment etc? At some point, how does insurance justify not covering the drug for patients https://t.co/Szkd9B96r8
The results, while unpublished, are the latest in a string of hopeful signs for weight loss drugs to treat a variety of conditions. https://t.co/1ViikUFUYw
The GLP-1 drug family drug RCT evidence list now includes: ✓ Diabetes ✓ Obesity ✓ Obesity + heart disease ✓ Obesity + heart failure w/ preserved EF ✓ Obesity + sleep apnea ✓ Prevention of kidney damage w/ diabetes Potential: —MASH (liver disease) —Parkinson's —Alzheimer's https://t.co/zUsNwJmmzt
It's been 20 years since this study was published in which primary care physicians were surveyed about #obesity and revealed several levels of #weightbias and #weightstigma Any chance these 620 physicians can be surveyed again today? @DrGaryFoster https://t.co/hNHjQUdklc https://t.co/DxIc8fS147
Obesity causes sleep apnea Treat underlying cause—> reduce sleep apnea Yet another win for GLP-1 receptor agonists 20% weight loss led to dramatic reduction in number of episodes of breathing stoppage at night. https://t.co/xI7ra0Y35L
Are We Missing Our Chance for Better Equity in Obesity Care? via @ConscienHealth https://t.co/y3SYMKlRNV
$RMD bagholders worst nightmares starting to become realized *Eli Lilly obesity therapy succeeds in late-stage trials for sleep disorder https://t.co/ANhAFcBiSK
All of the stuff we're seeing about the things GLP-1 drugs can treat...can make you wonder...just how many health problems are a result of, or tied to...obesity...and how many health problems can be mitigated...by simply losing weight? https://t.co/ZP65WXI8nR (via @AnnikaKimC…
$LLY reports late stage trial showed its weight loss GLP-1 is effective in treating obstructive Sleep Apnea. If approved by FDA, it would mean that Medicare will cover weight loss drugs for two medical conditions, following $NVO Wegovy approval for cardiac conditions. https://t.co/Riug8KvalP
Will advanced #ObesityMedicines meet their potential to reduce #HealthDisparities? Or make them worse? This is not the final word, but so far, it's not a looking good, say @LATkarenkaplan @HamletGasoyan @ObesityPsychMD @askdrfatima @eberly_lauren https://t.co/BG3H1uMr9g
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition. https://t.co/uImGnvVpGT
Will advanced #ObesityMedicines meet their potential to reduce #HealthDisparities? Or make them worse?This is not the final word, but so far, it's not a looking good, say @LATkarenkaplan @HamletGasoyan @ObesityPsychMD @askdrfatima @eberly_lauren https://t.co/BG3H1uMr9g
😴 SLEEP APNEA: another large market about to be over-run by the GLP-1 stampede https://t.co/BC4jhfywt1
Will advanced #ObesityMedicines meet their potential to reduce #HealthDisparities? Or make them worse. This is not the final word, but so far, it's not a looking good, say @LATkarenkaplan @HamletGasoyan @ObesityPsychMD @askdrfatima @eberly_lauren https://t.co/BG3H1uMr9g
Will advanced #ObesityMedicines meet their potential to reduce #HealthDisparities? Or make them worse. This is not the final word, but so far, it's not a looking good, say @LATkarenkaplan @HamletGasoyan @TBellW @ObesityPsychMD @askdrfatima @eberly_lauren https://t.co/BG3H1uMr9g
In 2019, @TheLancet Commission on Obesity released the report 'The Global Syndemic of Obesity, Undernutrition, and Climate Change'. The report called for an urgent and holistic approach to achieve better human and planetary health. ➡️ https://t.co/sabwUia2eW https://t.co/3KHPoprDQl
New study shows weight loss procedure beats out popular medication https://t.co/Cqqarcu3Lb https://t.co/g5OJNj8ivH
Living with Obesity: Navigating Stigma, Treatments, and Support — via @healthing_ca #ObesityAwareness #Healthcare https://t.co/9pbWzvdNTG